On January 17, 2024, Belgium inaugurated its new Health Data Agency, a project approved a year earlier. The agency is designed to improve the accessibility and reusability of health data for secondary purposes. This enhancement of data availability will be executed in a manner that ensures both security and adherence to privacy regulations.
Data types Involved
The data encompasses a broad spectrum. Founding members of the ADS (Sciensano, INAMI, SPF Public Health, KCE, AFPMS) have established a framework to map out the extensive data sets targeted, which include health, diseases, medical equipment and products, health determinants, related activities, etc. According to an agency program manager, this data will inherently be public and anonymized.
Structure of the Repository
The platform, as it currently stands, is relatively straightforward. It lists a variety of accessible datasets, while the agency itself does not hold the data. The data is organized using the DCAT_AP format.
Role of the Health Data Agency
The agency acts as an intermediary, facilitating the interaction between those who reuse data and the entities that own it. It offers tools and legal advice to aid in data exchange. Moreover, the agency is responsible for verifying the identity and intentions of data reusers, aligning its operations with the guidelines set forth by the European Health Data Space.
For further details, visit the Agency's website: https://hda.belgium.be/fr.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
FTC Completes Updates to Health Breach Notification Rule for Health Apps
The Federal Trade Commission announced it has finalized changes to the Health Breach Notification Rule (HBNR) that will strengthen and modernize the rule by clarifying its applicability to health apps and other similar technologies and expanding the information that covered entities must provide to consumers when notifying them of a breach of their health data.
The European Health Data Space overcomes its final obstacle in Parliament
iliomad is deligthed to have supported the ICM - Institut du Cancer de Montpellier in their CNIL's authorization process
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study. The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022. The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer. We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
